A Phase 1 interventional study of Panitumumab in Solid Tumors, sponsored by Amgen. Completed at 11 sites in United States. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2016-05-18.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study was to evaluate the safety and pharmacokinetics of up to 3 different dose schedules of panitumumab in pediatric patients with solid tumors.
This is an open-label, multi-center, single arm, dose-ranging, clinical study. Panitumumab will be administered by intravenous infusion to 4-6 patients per cohort. Three planned cohorts, stratified by age, will be studied at 100% of the recommended panitumumab dose for each treatment schedule as defined in adults. Enrollment will start with a 2.5 mg/kg once weekly administration to the 12 to \< 18 year old patients. Upon demonstration of sufficient safety additional cohorts will open; a 2.5 mg/kg once weekly administration to the 1 to \< 12 year old patients and a 6.0 mg/kg once every two weeks to the 12 to \< 18 year old patients. The decision to advance to the next cohort will be based on observance of ≤ 33% incidence of a dose limiting toxicity during the evaluation period. Subsequent cohorts of 6.0 mg/kg once every two weeks to the 1 to \< 12 year old patients and 9.0 mg/kg once every three weeks to both age groups will open once sufficient safety in each cohort is determined. Participants may stay on study treatment until disease progression.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received panitumumab at planned doses ranging from 2.5 mg/kg weekly (QW) to 9.0 mg/kg every 3 weeks (Q3W) until the patient experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study.
Biological: Panitumumab
Panitumumab administered by intravenous infusion
Also known as: Vectibix
Number of Participants With Dose-limiting Toxicities (DLTs)
Any panitumumab related grade 3 or 4 hematologic or non-hematologic toxicity (graded according to the modified Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria) was considered a DLT with the exception of alopecia and fatigue. Hypomagnesemia, nausea, diarrhea, vomiting, and skin or nail toxicities constituted a DLT only of the following occured: • Grade 3 or 4 hypomagnesemia that persisted for at least 5 days despite maximal magnesium replacement; • Grade 3 or 4 diarrhea, nausea, or vomiting that persisted for at least 5 days despite maximum supportive therapy; • Grade 4 skin or nail toxicity.
Time frame: 28 days from initial administration of panitumumab for the 2.5 and 6 mg/kg cohorts and 21 days from first administration for the 9 mg/kg cohort.
Number of Participants With Adverse Events (AEs)
A serious adverse event is defined as an AE that: • is fatal; • is life threatening; • requires in-patient hospitalization or prolongation of existing hospitalization; • results in persistent or significant disability/incapacity; • is a congenital anomaly/birth defect; • other significant medical hazard. The investigator assessed whether adverse events were related to panitumumab. The severity of adverse events was based on CTCAE version 3 (with the exception of skin- or nail-related toxicities which were graded using the CTCAE version 3.0 with modifications), according to the following: Grade 1 = Mild (aware of sign or symptom, but easily tolerated); Grade 2 = Moderate (discomfort enough to cause interference with usual activity); Grade 3 = Severe (incapacitating with inability to work or do usual activity); Grade 4 = Life-threatening or disabling; Grade 5 = Fatal.
Time frame: From first dose date to end of study date. The median duration of study was 47 days.
Maximum Observed Concentration (Cmax) of Panitumumab
Panitumumab serum concentration was measured using an enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) of the assay was 400 pg/mL. Concentrations below the LLOQ were set to zero.
Time frame: First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).
Minimum Observed Concentration (Cmin) of Panitumumab
Time frame: First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).
Area Under the Concentration-time Curve During the Dosing Interval (AUC0-tau) for Panitumumab
The area under the serum concentration-time curve from time zero to the end of the dosing interval (AUCtau), estimated using the linear trapezoidal method.
Time frame: First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).
Half-life (t1/2) for the Terminal Phase (First Dose) or Dosing Interval (Third Dose) of Panitumumab
Time frame: First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).
Serum Clearance (CL) of Panitumumab
Time frame: First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).
Number of Participants Who Developed Antibodies to Panitumumab
Three validated assays were used to detect the presence of anti-panitumumab antibodies. Two screening immunoassays, an acid-dissociation enzyme-linked immunosorbent assay (ELISA) and a Biacore-based biosensor assay, were used to detect antibodies capable of binding to panitumumab. All samples confirmed to be positive by drug specificity in either screening immunoassay were further tested for neutralizing antibodies in a cell-based epidermal growth factor receptor (EGFR) phosphorylation bioassay. The number of participants who developed antibodies to panitumumab is the number of participants with a non-positive (including missing) antibody result at baseline and a positive antibody result at any post-baseline time point.
Time frame: Before panitumumab administration on Day 1, Day 43, Day 169 and 30 days after last dose for all cohorts.
Percentage of Participants With an Objective Response
Disease assessments were based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria. A participant was considered a responder if their best response was either a complete or partial response. Participants without a post-baseline assessment were considered non-responders. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response (CR): Disappearance of all target and non-target lesions, normalization of tumor markers and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions, no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions, persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease (PD) or/and maintenance of tumor marker level above normal limits, and no new lesions.
Time frame: Tumor response was assessed every 8 weeks through week 48 and every 3 months thereafter until disease progression or end of study. The data cut-off for the analysis was 17 June 2015; median duration of study was 47 days.
Percentage of Participants With Disease Control
Disease assessments were based on investigator review of scans using modified RECIST version 1.0 criteria. A participant was considered to have disease control if their best response is either a complete or partial response, or stable disease. Participants without a post-baseline assessment were considered to not have disease control. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. A best overall response of SD requires a visit response of SD or better, no earlier than 49 days after the date of enrollment. Stable disease (SD): Neither sufficient shrinkage of target lesions to qualify for a PR nor sufficient increase to qualify for PD and no progression of existing non-target lesions and no new lesions.
Time frame: Tumor response was assessed every 8 weeks through week 48 and every 3 months thereafter until disease progression or end of study. The data cut-off for the analysis was 17 June 2015; median duration of study was 47 days.
This study was conducted at 7 centers in the United States. Participants were enrolled from 14 March 2008 to 4 March 2015.
| Milestone | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| Started | 6 | 7 | 4 | 6 | 8 |
| Completed | 1 | 5 | 4 | 4 | 3 |
| Not completed | 5 | 2 | 0 | 2 | 5 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 4 | 0 | 0 | 1 | 1 |
| Withdrew: Disease progression | 0 | 1 | 0 | 1 | 3 |
| Withdrew: Protocol-specified criteria | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 |
Any panitumumab related grade 3 or 4 hematologic or non-hematologic toxicity (graded according to the modified Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria) was considered a DLT with the exception of alopecia and fatigue. Hypomagnesemia, nausea, diarrhea, vomiting, and skin or nail toxicities constituted a DLT only of the following occured: • Grade 3 or 4 hypomagnesemia that persisted for at least 5 days despite maximal magnesium replacement; • Grade 3 or 4 diarrhea, nausea, or vomiting that persisted for at least 5 days despite maximum supportive therapy; • Grade 4 skin or nail toxicity.
| participants | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) | 1 | 0 | 0 | 1 | 3 |
Three validated assays were used to detect the presence of anti-panitumumab antibodies. Two screening immunoassays, an acid-dissociation enzyme-linked immunosorbent assay (ELISA) and a Biacore-based biosensor assay, were used to detect antibodies capable of binding to panitumumab. All samples confirmed to be positive by drug specificity in either screening immunoassay were further tested for neutralizing antibodies in a cell-based epidermal growth factor receptor (EGFR) phosphorylation bioassay. The number of participants who developed antibodies to panitumumab is the number of participants with a non-positive (including missing) antibody result at baseline and a positive antibody result at any post-baseline time point.
| participants | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| Binding antibodies | 1 | 0 | 0 | 2 | 0 |
| Neutralizing antibodies | 0 | 0 | 0 | 0 | 0 |
A serious adverse event is defined as an AE that: • is fatal; • is life threatening; • requires in-patient hospitalization or prolongation of existing hospitalization; • results in persistent or significant disability/incapacity; • is a congenital anomaly/birth defect; • other significant medical hazard. The investigator assessed whether adverse events were related to panitumumab. The severity of adverse events was based on CTCAE version 3 (with the exception of skin- or nail-related toxicities which were graded using the CTCAE version 3.0 with modifications), according to the following: Grade 1 = Mild (aware of sign or symptom, but easily tolerated); Grade 2 = Moderate (discomfort enough to cause interference with usual activity); Grade 3 = Severe (incapacitating with inability to work or do usual activity); Grade 4 = Life-threatening or disabling; Grade 5 = Fatal.
| participants | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| Any adverse event | 6 | 7 | 3 | 6 | 8 |
| Serious adverse events | 5 | 3 | 2 | 3 | 5 |
| Treatment-related adverse event | 5 | 5 | 3 | 5 | 6 |
| Treatment-related serious adverse event | 1 | 0 | 0 | 1 | 2 |
| Withdrawals due to adverse event | 0 | 0 | 0 | 0 | 0 |
| Grade 1 | 5 | 7 | 3 | 6 | 6 |
| Grade 2 | 5 | 6 | 3 | 4 | 7 |
| Grade 3 | 4 | 5 | 2 | 4 | 6 |
| Grade 4 | 4 | 0 | 0 | 1 | 2 |
| Fatal | 4 | 0 | 0 | 1 | 1 |
Panitumumab serum concentration was measured using an enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) of the assay was 400 pg/mL. Concentrations below the LLOQ were set to zero.
| μg/mL | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| First Dose (n=6, 7, 3, 4, 7) | 52.8 ± 11.4 | 161 ± 41.2 | 205 ± 45.9 | 42.9 ± 8.51 | 120 ± 29.4 |
| Third Dose (n=3, 5, 1, 3, 2) | 76.6 ± 21.1 | 187 ± 45.2 | 327 ± NA | 60.8 ± 15.7 | 126 ± NA |
| μg/mL | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| First Dose (n=4, 7, 2, 4, 5) | 6.62 ± 6.83 | 24.7 ± 18.6 | 35.3 ± NA | 4.87 ± 3.64 | 19.7 ± 15.5 |
| Third Dose (n=3, 5, 0, 3, 2) | 24.2 ± 22.9 | 48.1 ± 25.1 | NA ± NA | 17.3 ± 8.83 | 26.1 ± NA |
The area under the serum concentration-time curve from time zero to the end of the dosing interval (AUCtau), estimated using the linear trapezoidal method.
| day*μg/mL | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| First Dose (n=4, 7, 2, 4, 5) | 167 ± 86.1 | 1040 ± 357 | 1580 ± NA | 127 ± 37.9 | 708 ± 247 |
| Third Dose (n=3, 5, 0, 3, 2) | 306 ± 178 | 1330 ± 357 | NA ± NA | 255 ± 70.7 | 754 ± NA |
| days | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| First Dose (n=2, 5, 1, 3, 3) | 1.33 ± NA | 4.49 ± 1.09 | 4.27 ± NA | 2.11 ± 0.913 | 4.23 ± 1.64 |
| Third Dose (n=2, 2, 0, 1, 1) | 2.94 ± NA | 4.98 ± NA | NA ± NA | 3.07 ± NA | 4.91 ± NA |
| mL/day/kg | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| First Dose (n=3, 5, 1, 4, 3) | 19.8 ± 8.57 | 6.38 ± 0.466 | 7.15 ± NA | 18.7 ± 6.35 | 8.06 ± 1.40 |
| Third Dose (n=3, 5, 0, 3, 2) | 9.92 ± 4.40 | 4.69 ± 1.00 | NA ± NA | 10.1 ± 2.44 | 8.05 ± NA |
Disease assessments were based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria. A participant was considered a responder if their best response was either a complete or partial response. Participants without a post-baseline assessment were considered non-responders. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response (CR): Disappearance of all target and non-target lesions, normalization of tumor markers and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions, no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions, persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease (PD) or/and maintenance of tumor marker level above normal limits, and no new lesions.
| percentage of participants | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| Percentage of Participants With an Objective Response | 0.00 (0.00 to 60.24) | 0.00 (0.00 to 70.76) | 0.00 (0.00 to 60.24) | 0.00 (0.00 to 84.19) | 0.00 (0.00 to 70.76) |
Disease assessments were based on investigator review of scans using modified RECIST version 1.0 criteria. A participant was considered to have disease control if their best response is either a complete or partial response, or stable disease. Participants without a post-baseline assessment were considered to not have disease control. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. A best overall response of SD requires a visit response of SD or better, no earlier than 49 days after the date of enrollment. Stable disease (SD): Neither sufficient shrinkage of target lesions to qualify for a PR nor sufficient increase to qualify for PD and no progression of existing non-target lesions and no new lesions.
| percentage of participants | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| Percentage of Participants With Disease Control | 0.00 (0.00 to 60.24) | 33.33 (0.84 to 90.57) | 0.00 (0.00 to 60.24) | 50.00 (1.26 to 98.74) | 66.67 (9.43 to 99.16) |
Collected over From first dose date to end of study date. The median duration of study is 47 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Age 12-17: 2.5 mg/kg QW | — | 5/6 (83.3%) | 5/6 (83.3%) |
| Age 12-17: 6 mg/kg Q2W | — | 3/7 (42.9%) | 7/7 (100%) |
| Age 12-17: 9 mg/kg Q3W | — | 2/4 (50%) | 3/4 (75%) |
| Age 1-11: 2.5 mg/kg QW | — | 3/6 (50%) | 6/6 (100%) |
| Age 1-11: 6 mg/kg Q2W | — | 5/8 (62.5%) | 7/8 (87.5%) |
| Event | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| Haemoglobin decreasedInvestigations | 2/6 | 0/7 | 0/4 | 0/6 | 0/8 |
| TachycardiaCardiac disorders | 0/6 | 0/7 | 1/4 | 0/6 | 0/8 |
| PyrexiaGeneral disorders | 0/6 | 0/7 | 1/4 | 0/6 | 0/8 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/6 | 0/7 | 0/4 | 0/6 | 2/8 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/6 | 1/7 | 1/4 | 0/6 | 1/8 |
| HypotensionVascular disorders | 0/6 | 0/7 | 1/4 | 0/6 | 0/8 |
| Abdominal painGastrointestinal disorders | 1/6 | 0/7 | 0/4 | 0/6 | 0/8 |
| AscitesGastrointestinal disorders | 1/6 | 0/7 | 0/4 | 0/6 | 0/8 |
| PancreatitisGastrointestinal disorders | 1/6 | 0/7 | 0/4 | 0/6 | 0/8 |
| VomitingGastrointestinal disorders | 0/6 | 0/7 | 0/4 | 1/6 | 1/8 |
| Event | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W |
|---|---|---|---|---|---|
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 2/6 | 5/7 | 0/4 | 0/6 | 0/8 |
| VomitingGastrointestinal disorders | 0/6 | 0/7 | 1/4 | 4/6 | 1/8 |
| FatigueGeneral disorders | 1/6 | 4/7 | 2/4 | 0/6 | 2/8 |
| Dry skinSkin and subcutaneous tissue disorders | 0/6 | 4/7 | 2/4 | 1/6 | 3/8 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 0/7 | 2/4 | 0/6 | 0/8 |
| TachycardiaCardiac disorders | 0/6 | 0/7 | 2/4 | 0/6 | 1/8 |
| Abdominal painGastrointestinal disorders | 2/6 | 1/7 | 2/4 | 0/6 | 0/8 |
| ConstipationGastrointestinal disorders | 3/6 | 3/7 | 1/4 | 1/6 | 0/8 |
| Chest painGeneral disorders | 0/6 | 0/7 | 2/4 | 0/6 | 0/8 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/6 | 0/7 | 2/4 | 0/6 | 0/8 |
| Age, Continuous(years) | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W | Total |
|---|---|---|---|---|---|---|
| Mean | 13.2 ± 0.8 | 15.6 ± 1.5 | 15.8 ± 1.9 | 7.8 ± 3.1 | 8.4 ± 2.8 | 11.8 ± 4.1 |
| Sex: Female, Male(Participants) | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 1 | 3 | 3 | 4 | 14 |
| Male | 3 | 6 | 1 | 3 | 4 | 17 |
| Race/Ethnicity, Customized(participants) | Age 12-17: 2.5 mg/kg QW | Age 12-17: 6 mg/kg Q2W | Age 12-17: 9 mg/kg Q3W | Age 1-11: 2.5 mg/kg QW | Age 1-11: 6 mg/kg Q2W | Total |
|---|---|---|---|---|---|---|
| Asian | 0 | 2 | 0 | 0 | 0 | 2 |
| Black (or African American) | 1 | 1 | 0 | 1 | 0 | 3 |
| Hispanic or Latino | 0 | 0 | 1 | 0 | 1 | 2 |
| Other | 0 | 0 | 0 | 1 | 0 | 1 |
| White or Caucasian | 5 | 4 | 3 | 4 | 7 | 23 |
The record gives a start of Mar 2008, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab